The cochlea converts sound waves into electrical nerve signals through an exquisitely precise ionic mechanism. Connexin 26, encoded by GJB2¹¹ Connexin 26, encoded by GJB2
Gap Junction Protein Beta-2; the most common gene for hereditary non-syndromic hearing loss worldwide forms the gap junction channels in cochlear support cells that maintain this mechanism. The c.235delC frameshift deletion — rs80338943 in the GeneOps database — eliminates connexin 26 function entirely. It is the dominant hereditary deafness allele across East Asia, carried by roughly 1 in 100 Chinese, Japanese, and Korean individuals, and is the most important single genetic cause of severe prelingual hearing loss in these populations.

Unlike the V37I missense variant, which partially reduces gap junction activity and causes mild-to-moderate hearing loss, c.235delC is a null allele: it abolishes protein function completely. Two copies produce severe-to-profound congenital sensorineural hearing loss in the vast majority of cases. The mutation arose from a single ancestral founder in East Asia, explaining its ethnic specificity and absence in European and African populations.

The Mechanism

The c.235delC deletion removes a cytosine at position 235 of the GJB2 coding sequence (on the coding strand; the gene lies on the minus strand of chromosome 13). This one-base frameshift shifts the reading frame beginning at codon 79, generating a premature stop codon three positions later: p.Leu79Cysfs*3²² p.Leu79Cysfs*3
The truncated protein is only 81 amino acids long — less than one-third the normal 226 amino acids.

The truncated peptide lacks the second through fourth transmembrane domains, the cytoplasmic loop, and the C-terminal tail — structures required for hexamer assembly and membrane targeting. Nonsense-mediated mRNA decay³³ Nonsense-mediated mRNA decay
A cellular pathway that degrades transcripts with premature stop codons, preventing synthesis of potentially dominant-negative truncated proteins likely eliminates most of the aberrant mRNA. No functional connexin 26 reaches the cell membrane in homozygotes. The result is the same functional null state as c.35delG in Europeans: complete loss of cochlear gap junction channels, failure of potassium ion recycling through the supporting cell network, collapse of the endocochlear potential, and hair cell death.

The Evidence

The East Asian specificity and founder effect of c.235delC were established by Yan et al. — Human Genetics 2003, PMID 14505035⁴⁴ Yan et al. — Human Genetics 2003, PMID 14505035, which demonstrated significant linkage disequilibrium between the mutation and five flanking markers, and its presence exclusively in East Asian populations absent from Caucasians — consistent with a single ancestral origin after the divergence of East Asian and European lineages.

The mutation burden in deaf populations across China was quantified by Chan et al. — Genetics in Medicine 2007, PMID 17505205⁵⁵ Chan et al. — Genetics in Medicine 2007, PMID 17505205: among 3,004 nonsyndromic hearing-impaired Chinese patients, 16.3% carried at least one c.235delC allele, with 7.8% homozygous and 8.5% heterozygous. The carrier frequency in healthy Chinese controls was approximately 1.4%.

The risk conferred by homozygous c.235delC was quantified by Dai et al. — Journal of Translational Medicine 2012, PMID 22747691⁶⁶ Dai et al. — Journal of Translational Medicine 2012, PMID 22747691, a meta-analysis of 36 studies covering 13,217 cases and 6,521 controls: the overall odds ratio for non-syndromic hearing loss was 7.9 (95% CI 4.77–13.11), rising to 12.05 (95% CI 8.33–17.44) in the East and Southeast Asian subgroup. No significant association was found in European or Oceanian populations, confirming the East Asian specificity.

Phenotypic characterisation of 244 patients with homozygous c.235delC by Guo et al. — Neural Plasticity 2020, PMID 32802038⁷⁷ Guo et al. — Neural Plasticity 2020, PMID 32802038 found that 71.9% had profound hearing loss (>90 dB HL) and 14.3% severe loss (70–90 dB HL), with 63.9% showing bilateral asymmetry in severity or audiogram shape. A complementary Frontiers in Cell and Developmental Biology 2021 study (PMC7953049)⁸⁸ Frontiers in Cell and Developmental Biology 2021 study (PMC7953049) of 295 homozygotes identified a small but important phenotypic minority: 1.36% had post-lingual onset and 2.71% had prelingual moderate-only hearing loss, suggesting that unidentified modifier genes can partially compensate for c.235delC null status.

Genotype-phenotype data from the largest international GJB2 consortium — Snoeckx et al. — 1,531 biallelic cases, PMID 16380907⁹⁹ Snoeckx et al. — 1,531 biallelic cases, PMID 16380907 — confirmed that biallelic truncating mutations (including c.235delC) produce significantly more severe hearing loss than non-truncating genotypes (p<0.0001), with profound loss in 64% and severe in 25% of truncating homozygotes.

A notable edge case was reported by Xia et al. — Genetics and Molecular Biology 2019, PMID 30816908¹⁰¹⁰ Xia et al. — Genetics and Molecular Biology 2019, PMID 30816908: a patient with homozygous c.235delC presented with auditory neuropathy spectrum disorder (ANSD) features — absent auditory brainstem responses with some preserved otoacoustic emissions — representing the first documented ANSD presentation for this genotype. This case expands the phenotypic spectrum and underscores the importance of comprehensive audiological evaluation beyond simple pure-tone thresholds.

Practical Actions

For the vast majority of homozygous c.235delC individuals (DD genotype), hearing loss is severe to profound and presents in early childhood or at birth. The most impactful intervention is early cochlear implantation: GJB2-related deafness leaves the auditory nerve structurally intact, making CI outcomes among the best of any deafness etiology. Takahashi et al. — PMID 21292415¹¹¹¹ Takahashi et al. — PMID 21292415 confirmed threshold improvement after CI in all 16 homozygous c.235delC recipients studied.

The 1-3-6 milestone framework from the Joint Committee on Infant Hearing — hearing screening completed by one month, diagnosis confirmed by three months, early intervention started by six months — is the clinical standard that maximises speech and language development. Early genetic diagnosis via GJB2 sequencing can accelerate this timeline by providing the aetiology before audiology confirms severity.

Single heterozygous carriers (DI genotype) have normal hearing; their significance is exclusively reproductive. When two carriers conceive a child, each pregnancy has a 25% chance of biallelic c.235delC and severe-to-profound hearing loss.

Interactions

The most clinically significant compound heterozygous configuration in East Asian populations is c.235delC in trans with V37I (rs72474224). Because V37I is a partial loss-of-function allele while c.235delC is a complete null, compound heterozygotes typically show hearing loss of intermediate severity — milder than c.235delC homozygotes but more significant than V37I homozygotes. Some c.235delC/V37I compound heterozygotes have reportedly presented with borderline-normal audiograms, highlighting the V37I allele's partial preservation of gap junction function.

In East Asian populations with one c.235delC allele and unexplained sensorineural hearing loss, full GJB2 sequencing is essential to identify a second pathogenic allele on the opposite chromosome, including other frameshift variants such as c.167delT (rs80338942), and to test for large GJB6 gene deletions (del(GJB6-D13S1830) and del(GJB6-D13S1854)) that act as pathogenic second alleles for any GJB2 pathogenic variant.

TRPV1 is the molecular gateway to pain in your sensory neurons, a calcium channel that opens in response to noxious heat (above 43°C), acids, and capsaicin — the compound that makes chili peppers burn. The Ile585Val variant¹¹ Ile585Val variant
rs8065080, also known as I585V or c.1191A>G, causes an amino acid substitution from isoleucine to valine at position 585 of the TRPV1 protein affects how sensitively this channel responds to pain-inducing stimuli.

TRPV1 isn't just a heat sensor. When tissue injury occurs, inflammatory mediators like bradykinin and prostaglandins sensitize TRPV1²² inflammatory mediators like bradykinin and prostaglandins sensitize TRPV1
lowering its activation threshold from ~43°C to as low as 34°C, which is why inflamed tissue hurts even at body temperature. This sensitization process is central to chronic pain conditions, making genetic variants in TRPV1 clinically meaningful beyond simple thermal sensitivity.

The Mechanism

The Ile585Val substitution sits in a critical region of the TRPV1 channel near the S4-S5 linker, an area involved in channel gating and sensitivity to vanilloid ligands like capsaicin. The isoleucine at position 585 is a hydrophobic amino acid; replacing it with valine (also hydrophobic but slightly smaller) appears to alter the channel's conformational response to activation³³ appears to alter the channel's conformational response to activation
studies suggest the Val variant may change channel morphology or stimulus-dependent gating.

Functional studies show that Val-Val carriers (GG genotype) exhibit higher capsaicin sensitivity⁴⁴ Val-Val carriers (GG genotype) exhibit higher capsaicin sensitivity
measured as lower detection thresholds for capsaicin-induced burning, while Ile-Ile carriers demonstrate reduced sensitivity to thermal pain, capsaicin, and inflammatory pain. The heterozygous state shows intermediate function, consistent with codominant inheritance.

The Evidence

The most compelling evidence comes from a meta-analysis of 8,220 individuals across seven cohorts⁵⁵ meta-analysis of 8,220 individuals across seven cohorts
Valdes et al. genotyped 3,270 symptomatic knee osteoarthritis cases, 1,098 asymptomatic OA cases, and 3,852 controls from the UK, USA, and Australia. The Ile-Ile genotype was associated with 25% lower risk of symptomatic knee OA compared to healthy controls (OR 0.75, 95% CI 0.64-0.88, p=0.00039) after adjusting for age, sex, and BMI. Crucially, no difference was seen between asymptomatic OA cases and controls, suggesting the genetic effect operates through pain perception rather than joint damage itself.

A Japanese study of 134 healthy adults⁶⁶ Japanese study of 134 healthy adults
Okamoto et al. measured burning pain thresholds using a 48°C hot plate and capsaicin sensitivity using topical application. Val-Val homozygotes showed significantly higher capsaicin sensitivity compared to Ile carriers, though associations with thermal pain were more complex, likely due to redundancy in heat-sensing mechanisms (TRPV1, TRPA1, TRPM3 all contribute).

A controlled study of 25 healthy volunteers⁷⁷ controlled study of 25 healthy volunteers
subjects with the GG genotype showed 82% less capsaicin-induced warm hypoesthesia and 22% less heat pain sensitivity gain after topical capsaicin compared to AA/AG carriers, demonstrating altered channel function under physiological conditions.

A preliminary study of 46 migraine patients⁸⁸ preliminary study of 46 migraine patients
AA genotype frequency was 61% in chronic migraine patients versus 34% in episodic migraine and 38% in controls, with complete absence of GG genotype in chronic migraine group, though a subsequent larger study and meta-analysis failed to replicate this association⁹⁹ subsequent larger study and meta-analysis failed to replicate this association
349 migraine patients showed no significant difference in rs8065080 genotype distribution.

Interestingly, a Korean diabetes study of 8,842 subjects¹⁰¹⁰ Korean diabetes study of 8,842 subjects
minor allele (Ile/A) carriers had lower HOMA-IR and reduced type 2 diabetes risk specifically when consuming high-fat diets, suggesting gene-nutrient interactions beyond pain perception.

Practical Implications

Your rs8065080 genotype influences how you experience pain from heat, inflammation, and irritating chemicals. Ile-Ile carriers (AA) experience less intense pain from these stimuli and may have higher pain tolerance, while Val-Val carriers (GG) are more sensitive and may be more prone to chronic pain conditions when tissue damage is present.

This has implications for spicy food tolerance — Val carriers genuinely experience capsaicin as more intensely burning. It may also influence susceptibility to chronic pain syndromes where TRPV1 sensitization plays a role, including inflammatory arthritis, neuropathic pain, and potentially migraine (though evidence is mixed).

For thermal injury prevention, Val carriers' higher sensitivity may offer some protective benefit by triggering withdrawal reflexes earlier. However, in chronic inflammation, this same sensitivity may amplify pain signaling and contribute to disability even when structural damage is modest.

Interactions

TRPV1 rs8065080 has been studied alongside other TRPV1 coding variants, including rs222747 (M315I) and rs222749 (P91S)¹¹¹¹ rs222747 (M315I) and rs222749 (P91S)
both also affect TRPV1 function and pain perception. While these variants show linkage disequilibrium in some populations, their combined effects on pain perception have not been systematically characterized in compound heterozygote studies.

TRPV1 functionally interacts with TRPA1 (a chemical irritant receptor)¹²¹² TRPA1 (a chemical irritant receptor)
both channels can heterodimerize and TRPA1 variants also modulate heat and capsaicin sensitivity. The combined genotype effects remain an area of active research.

Since TRPV1 is upregulated by inflammatory mediators, genetic variants affecting inflammatory pathways (COX-2, TNF-alpha signaling) may interact with TRPV1 variants to modulate chronic pain risk, though specific gene-gene interaction studies are lacking.

On chromosome 6, in the most gene-dense stretch of the human genome, sits rs9271366 — an intergenic eQTL¹¹ eQTL
An expression quantitative trait locus: a genetic variant that influences how much of a nearby gene is produced, rather than changing the protein structure itself positioned between HLA-DQA1 and HLA-DRB1. The G allele of rs9271366 tags the DR15 haplotype²² DR15 haplotype
A co-inherited block of HLA alleles: DRB1*15:01 + DQA1*01:02 + DQB1*06:02. These three genes are inherited together so frequently in European populations that detecting one tag SNP can identify the whole block, the classical HLA class II combination that is the single strongest genetic risk factor for multiple sclerosis. Together with rs3135388 (which tags DRB1*15:01 from the DRB1 side), this SNP forms a two-SNP panel for DR15 haplotype detection — capturing the DQA1 regulatory dimension that the DRB1 tag alone cannot fully resolve.

HLA-DQA1 encodes the alpha chain of the HLA-DQ class II heterodimer. This chain partners with HLA-DQB1 to form the antigen-presenting surface on dendritic cells, macrophages, and B cells — the front line of adaptive immune surveillance. The specific combination DQA1*01:02/DQB1*06:02 encoded by the DR15 haplotype creates a peptide-binding groove that, in concert with DRB1*15:01, generates an unusually permissive environment for central nervous system self-antigen presentation. Research has shown that DQA1*01:02 can form a mixed-isotype heterodimer³³ mixed-isotype heterodimer
An HLA-DQ molecule assembled from chains encoded by different classical HLA-DR and DQ loci — in this case DQA1*01:02 pairing with DRB1*15:01 — creating an antigen-presenting complex not predicted from either gene alone with DRB1*15:01, expanding the repertoire of myelin peptides that can be displayed to auto-reactive T cells beyond what each molecule presents independently.

The Mechanism

rs9271366 sits approximately 9,100 bp downstream of HLA-DQA1 and 29,200 bp upstream of HLA-DRB1, placing it in the regulatory landscape shared by both genes. As an eQTL, the G allele is associated with altered HLA class II gene expression within the DR15 haplotype block. The entire block is in strong linkage disequilibrium⁴⁴ linkage disequilibrium
Alleles that are inherited together more often than expected by chance, forming a haplotype. LD means that the G allele of rs9271366 is an excellent proxy for the presence of DRB1*15:01, DQA1*01:02, and DQB1*06:02 on the same chromosome, meaning that detecting the G allele of rs9271366 reliably indicates the presence of the full three-gene MS-risk haplotype. The DRB1 expression data from the companion SNP rs3135388 confirms that A allele carriers (who also carry the DR15 block) show 8.3-fold higher DRB1 and 15.7-fold higher DQB1 expression, flooding antigen-presenting cells with the MS-risk isoform. The rs9271366 G allele captures this same regulatory state from the DQA1 side of the haplotype.

Within the DR15 haplotype, DQA1*01:02 participates in a unique mechanistic pathway. When myelin peptides that bind well to DRB1*15:01 are exhausted or when the standard DRB1-DRA heterodimer is unavailable, the DQA1*01:02/DRB1*15:01 mixed-isotype complex can present oligodendrocyte-specific protein (OSP) epitopes to CD4+ T cells — effectively broadening the antigenic targets available to auto-reactive cells and creating backup pathways for CNS autoimmunity.

The Evidence

The MS association of rs9271366-G reached P = 7 × 10⁻¹⁸⁴ with OR approximately 2.78 in GWAS Catalog aggregated data — one of the most statistically replicated findings in human genetics. A biorepository-linked EHR study⁵⁵ biorepository-linked EHR study
Restrepo et al. analysed 28 autoimmune disease SNPs in electronic health record-linked biobank participants replicated rs9271366 as a hallmark MS SNP with OR 1.91 (p=0.008) and confirmed shared genetic architecture with rheumatoid arthritis and Crohn's disease. An Italian relapsing-remitting MS study⁶⁶ Italian relapsing-remitting MS study
Sorosina et al., 161 untreated RRMS patients with full HLA imputation from WGS found rs9271366 among five MHC loci associated with T-cell receptor diversity — carriers show expanded T-cell clonotypes, consistent with chronic autoantigen-driven T-cell expansion targeting the CNS.

The association extends across autoimmune conditions. For SLE in Hispanic/Dominican patients⁷⁷ SLE in Hispanic/Dominican patients
Liu et al., 201 SLE cases and 205 controls from the Dominican Republic, rs9271366 as a DRB1*15:01 tag SNP showed the highest SLE risk among 13 tested MHC alleles (OR=3.5, p=8.7×10⁻¹⁰). In African American women⁸⁸ African American women
Ruiz-Narvaez et al., Women's Health Study cohort, it was the most strongly associated MHC SNP for SLE (OR=1.70, p=5.6×10⁻⁵), confirming that the DR15 haplotype drives SLE risk across ancestries where this haplotype is present. In Malay and Chinese populations⁹⁹ Malay and Chinese populations
Chai et al., 790 Malaysian subjects, the G allele and GG genotype significantly increased SLE susceptibility, with a DR15-tagged haplotype (GC at rs9271366/rs9275328) reaching genome-wide significance after permutation.

The gene-environment interaction with Epstein-Barr virus documented for the companion DRB1 tag (rs3135388) applies equally here, because both SNPs tag the same haplotype. HLA-DRB1*15:01 acts as a co-receptor for EBV infection of B cells¹⁰¹⁰ HLA-DRB1*15:01 acts as a co-receptor for EBV infection of B cells
Sundqvist et al., demonstrating the mechanistic link between the two strongest known MS risk factors. G allele carriers have more DR15 co-receptor surface available for viral entry, potentially sustaining higher EBV loads, more robust EBNA-1 antibody responses, and higher rates of molecular mimicry against myelin antigens.

Practical Implications

rs9271366 provides complementary information to rs3135388: both tag the DR15 haplotype, but from different positions flanking the DQA1/DRB1 locus. When both SNPs are available (as with WGS or comprehensive genotyping arrays), concordant G-at-rs9271366 and A-at-rs3135388 readings provide higher-confidence DR15 identification than either alone. When only one is available, each serves as a reliable proxy with >95% sensitivity.

The practical actions are shared with the DRB1 tag: vitamin D optimization to dampen the VDRE-driven upregulation of the DR15 allele, and vigilance for early MS symptoms. The vitamin D response element (VDRE) in the HLA-DRB1*15:01 promoter means that vitamin D insufficiency may directly increase expression of the MS-risk isoform in G allele carriers; maintaining serum 25(OH)D above 40 ng/mL is the most evidence-backed modifiable intervention for this haplotype. Approximately 25–30% of Europeans carry at least one DR15 chromosome, but lifetime MS risk remains approximately 1–3% for heterozygotes — HLA is necessary but not sufficient.

Interactions

rs9271366 and rs3135388 are in strong LD and tag the same DR15 haplotype from flanking positions. They are partner SNPs in the GeneOps dual-panel for DR15 detection: concordant results provide the highest confidence, while discordance may reflect genotyping error or, rarely, a partial haplotype. The DQA1*01:02/DRB1*15:01 mixed-isotype heterodimer effect is relevant specifically to rs9271366 as the DQA1-proximal tag: it captures the DQA1*01:02 allele that forms this cross-isotype antigen-presenting complex. Interactions with rs2187668 (HLA-DQ2.5 tag for celiac/T1D) and rs7454108 (HLA-DQ8 tag for T1D) concern distinct haplotype blocks and are not additive for MS risk. The IBD association of rs9271366 reflects a different alternate allele (C) tagging DRB1*15:02, which is unrelated to the G allele DR15 MS-risk signal analyzed here.

On chromosome 6, tucked in the intergenic stretch between HLA-DQB1 and HLA-DQA2 at position 32,699,045 (GRCh38), sits rs9275328 — the third pillar of the DR15 haplotype tag panel. Its C allele marks the presence of DQB1*06:02¹¹ DQB1*06:02
The HLA-DQ beta-1 chain allele that completes the DR15 haplotype: DRB1*15:01 + DQA1*01:02 + DQB1*06:02. These three genes are so tightly co-inherited across populations that a single SNP in each flanking region can identify the whole haplotype block with high accuracy, the allele that encodes the DQ beta chain partnering with DQA1*01:02 to form the most strongly MS-associated HLA-DQ heterodimer known. Together with rs3135388 (DRB1 side) and rs9271366 (DQA1 side), this SNP closes a three-locus surveillance net: when all three risk alleles are present, the DR15 haplotype is identified with the highest possible confidence from standard genotyping data.

HLA-DQB1 encodes the beta chain of the HLA-DQ class II antigen-presenting molecule. The beta chain forms the floor and one wall of the peptide-binding groove, and DQB1*06:02 creates a groove geometry that, in combination with the DQA1*01:02 alpha chain, is uniquely permissive for presenting myelin and oligodendrocyte peptides to auto-reactive CD4+ T cells. This same DQA1*01:02/DQB1*06:02 combination also drives narcolepsy risk through a distinct mechanism: it presents hypocretin-neuron-derived peptides that, after molecular mimicry triggered by viral infection or vaccination, are targeted by cytotoxic immune responses that destroy the hypothalamic hypocretin-producing neurons responsible for wakefulness regulation.

The Mechanism

rs9275328 sits approximately 31 kb downstream of the HLA-DQB1 gene body (GRCh38 gene end ~32,668,383; SNP at 32,699,045) and approximately 2 kb upstream of HLA-DQA2. Like rs9271366, it functions as a haplotype tag in strong linkage disequilibrium²² linkage disequilibrium
LD with D'=0.941 between rs9271366 and rs9275328 (Chai et al. 2013), meaning the two alleles are almost always inherited together; r²=0.065 indicates they are not perfectly correlated but the haplotype GC tags a consistent biological state with the DQB1*06:02 allele across the DR15 haplotype block.

The C allele of rs9275328 is the DR15 haplotype allele. The T allele marks non-DR15 chromosomes and, when present as a heterozygote (CT), breaks up the homozygous DR15 state — which is why the CT genotype itself showed a protective OR in the Chai SLE cohort. The high DQB1 expression³³ high DQB1 expression
15.7-fold higher DQB1 expression in DR15 haplotype carriers documented in the rs3135388 eQTL study applies here too: the C allele at rs9275328 co-segregates with all the regulatory machinery driving elevated DRB1*15:01, DRB5*01:01, and DQB1*06:02 expression. The DQB1*06:02 beta chain is expressed on all antigen-presenting cell surfaces in CC homozygotes, dramatically increasing the capacity for DR15-type self-antigen presentation in the thymus and periphery.

The Evidence

The SLE evidence is direct. Chai et al. 2013⁴⁴ Chai et al. 2013
360 Malaysian SLE patients vs 430 healthy controls across Malay, Chinese, and Indian ethnicities; TaqMan genotyping of both rs9275328 and rs9271366 found that the C allele and CC genotype at rs9275328 increased SLE susceptibility in Malays and Chinese (OR > 1, p < 0.05), while the minor T allele and CT heterozygotes were protective (OR < 1, p < 0.05). The haplotype GC (rs9271366-G / rs9275328-C) reached genome-wide significance after 10,000 permutation tests. Multifactor dimensionality reduction testing identified the GG/CC and AG/CC genotype combinations as the high-risk class, directly implicating rs9275328-CC as a required component of the highest-risk SLE genotype.

For MS, the DQB1*06:02 allele that rs9275328-C tags has well-established independent risk contribution. Fine-mapping the MHC in MS⁵⁵ Fine-mapping the MHC in MS
International MHC fine-mapping studies across thousands of patients established that the full DR15 haplotype (DRB1*15:01/DQA1*01:02/DQB1*06:02) drives MS risk, with heterozygous DR15 carriers at OR approximately 2.1–2.8 and homozygotes at OR approximately 4–6 compared to non-carriers. The DQB1*06:02 beta chain forms the antigen-presenting surface that displays myelin peptides⁶⁶ antigen-presenting surface that displays myelin peptides
Including MBP, MOG, and OSP peptides that are targets of auto-reactive CD4+ T cells in MS — a function independent of DRB1*15:01 that explains why DQB1*06:02 adds to MS risk beyond the DRB1 contribution alone.

Narcolepsy adds a third condition to this SNP's profile. A systematic meta-analysis across four ethnic groups⁷⁷ A systematic meta-analysis across four ethnic groups
Liblau et al. 2018, 30,000+ subjects found HLA-DQB1*06:02 confers an odds ratio of 24.1 (CI 14.6–39.5) for narcolepsy type 1 — one of the largest genetic effect sizes recorded for any common variant. Over 90% of narcolepsy with cataplexy patients in European and East Asian populations carry at least one copy of DQB1*06:02, compared to 15–25% of controls. rs9275328-C, as a tag for this allele, captures this extraordinary narcolepsy susceptibility signal.

Practical Implications

rs9275328-C completes the three-SNP DR15 panel alongside rs3135388 and rs9271366. When all three risk alleles are concordant (A at rs3135388, G at rs9271366, C at rs9275328), DR15 haplotype identification is near-certain from standard genotyping data. For CC homozygotes with both other DR15 tags also homozygous, the combined evidence represents the highest HLA-based MS and narcolepsy genetic risk configuration captured by this platform.

The modifiable intervention is the same as for the other two DR15 tags: vitamin D optimization. The vitamin D response element in the DRB1*15:01 promoter⁸⁸ vitamin D response element in the DRB1*15:01 promoter
Ramagopalan et al. 2009 — the VDR binding site in the DRB1*15:01 promoter means vitamin D directly regulates expression of the MS-risk allele operates across the whole haplotype block, and DQB1*06:02 expression co-varies with DRB1*15:01 regulation. Vitamin D insufficiency may amplify DR15 allele expression; maintaining serum 25(OH)D above 40 ng/mL is the primary evidence-backed modifiable lever.

For narcolepsy, the key practical implication is recognising excessive daytime sleepiness combined with sudden muscle weakness triggered by strong emotions (cataplexy) as a specific clinical pattern warranting hypocretin/orexin testing. Early diagnosis enables treatment with sodium oxybate or pitolisant that dramatically improves quality of life.

Interactions

rs9275328 is the DQB1-side tag for the same DR15 haplotype block tagged by rs3135388 (DRB1 side) and rs9271366 (DQA1 side). In the Chai SLE study, the haplotype GC (rs9271366-G + rs9275328-C) and the MDR high-risk combination GG/CC (rs9271366/rs9275328) demonstrated multiplicative interaction: homozygous DR15 at both loci produced the highest SLE risk class. The DR15 haplotype block has D'=0.941 between rs9271366 and rs9275328, indicating very strong but not perfect LD — meaning the two SNPs occasionally separate on different chromosomes, and concordant genotyping across all three tag SNPs reduces false positive/negative haplotype calls. The narcolepsy risk from DQB1*06:02 is partially separable from the MS risk of the full DR15 haplotype: DQA1*01:02 is required as co-receptor partner for narcolepsy, making the DQA1/DQB1 pair (captured by rs9271366 + rs9275328) the most proximal genetic risk unit for narcolepsy type 1.

Every human's capacity for learning sits at the intersection of genetics and experience. Among the thousands of common variants that nudge cognitive development, one stands apart for reproducibility: rs9320913, a regulatory variant upstream of POU3F2¹¹ POU3F2
also called BRN-2 (Brain-2); a POU-domain transcription factor essential for the differentiation of cortical neurons and the generation of upper-layer neocortical neurons on chromosome 6. First identified as the lead GWAS hit for educational attainment in Rietveld et al. 2013²² Rietveld et al. 2013
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 340:1467–1471, rs9320913 has replicated in every large-scale follow-up, including the million-person Lee et al. 2018 study. The A allele at this locus is associated with approximately one month less schooling per copy — a small effect per variant, but the effect is among the most reliably detected cognitive GWAS signals in human genetics.

The Mechanism

rs9320913 sits in an intergenic region upstream of POU3F2, where it is thought to influence gene expression in fetal and adult brain tissue. POU3F2 encodes a transcription factor³³ transcription factor
a protein that binds DNA and controls which genes are switched on or off in a cell; POU3F2 is a master regulator of neuronal identity programs that is indispensable for cortical neuron differentiation. It governs the transition from direct to indirect neurogenesis — the cellular process that expands the neocortex and generates the upper-layer neurons responsible for higher cognition — and remains expressed in the adult brain, where it supports ongoing hippocampal neurogenesis and working memory.

POU3F2 regulates downstream genes involved in synaptic connectivity, including members of the neurexin family. Neurexins (including NRXN1) are synaptic cell-adhesion molecules that organise NMDA receptor scaffolding; disrupted neurexin expression alters NMDA receptor⁴⁴ NMDA receptor
N-methyl-D-aspartate receptor; the glutamate receptor subtype central to long-term potentiation (LTP) and the molecular basis of memory formation function and synaptic plasticity. This pathway — POU3F2 → neurexin signalling → NMDA receptor function → LTP — is one mechanistic bridge between the rs9320913 regulatory locus and variation in cognitive performance.

The Evidence

The foundational study is Rietveld et al. 2013⁵⁵ Rietveld et al. 2013
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 340:1467–1471, which identified rs9320913 as one of three genome-wide significant SNPs for years of schooling (P < 5×10⁻⁸). The effect size — approximately 0.10 standard deviations, or about one month of schooling per A allele — appears small, but this is expected for a highly polygenic trait. In Lee et al. 2018⁶⁶ Lee et al. 2018
Gene discovery and polygenic prediction from a GWAS of educational attainment in 1.1 million individuals. Nature Genetics 50:1112–1121, which extended the analysis to 1.1 million participants, 1,271 independent genome-wide significant SNPs were discovered and polygenic scores based on all common variants now explain 11–13% of the variance in educational attainment — a substantial fraction for any complex behavioural trait. The locus has also been replicated in the intermediate Okbay et al. 2016⁷⁷ Okbay et al. 2016
Genome-wide association study identifies 74 loci associated with educational attainment. Nature 533:539–542 study (N=293,723).

The biological plausibility is supported by mouse models. Hashizume et al. 2018⁸⁸ Hashizume et al. 2018
POU3F2 participates in cognitive function and adult hippocampal neurogenesis via mammalian-characteristic amino acid repeats. Genes Brain Behav demonstrated that mice with disrupted POU3F2 function show impaired object recognition memory and spatial memory, and reduced production of new neurons in the adult hippocampus — directly implicating POU3F2 in postnatal learning and memory circuits. Notaras et al. 2022⁹⁹ Notaras et al. 2022
Schizophrenia is defined by cell-specific neuropathology. Molecular Psychiatry 27:1416–1434 showed that BRN2 (POU3F2) is severely depleted in schizophrenia-derived neural progenitors, and lentiviral BRN2 rescue restores neuron production — establishing BRN2 as non-redundant for neuronal differentiation in human brain tissue.

Practical Actions

The A allele's effect operates through a neurodevelopmental pathway involving NMDA receptor function. The NMDA receptor requires three co-factors for full activation: glutamate (its primary agonist), glycine or D-serine (obligatory co-agonist at the GluN1 subunit), and magnesium (voltage-dependent channel blocker that sets the activation threshold). Magnesium L-threonate crosses the blood-brain barrier more efficiently than other magnesium salts and has been shown in a placebo-controlled RCT to improve executive function in adults with cognitive complaints (Liu et al. 2016¹⁰¹⁰ Liu et al. 2016
Efficacy and Safety of MMFS-01 for Treating Cognitive Impairment in Older Adults. J Alzheimer's Disease 48:353–364). Glycine, as an obligatory NMDA co-agonist, is reliably present in adequate dietary amounts for most people, but targeted glycine supplementation has been studied for cognitive enhancement in contexts where NMDA hypofunction is suspected. Zinc is an endogenous NMDA modulator that gates channel conductance and has bidirectional effects depending on concentration.

For CC individuals: no specific intervention is indicated at this locus. The POU3F2 regulatory region is functioning in the population-typical range.

Interactions

rs9320913 is one of three early landmark SNPs for educational attainment (rs11584700 near NRXN1 and rs4851266 near KCTD13 were the others identified in Rietveld 2013). NRXN1 is a neurexin directly involved in NMDA receptor scaffolding, making rs11584700 a pathway partner: both SNPs converge on synaptic plasticity and NMDA function, though via different molecular nodes. The Lee et al. 2018 polygenic score, which aggregates effects from 1,271 loci, substantially outperforms any individual SNP for prediction — the real clinical utility of rs9320913 lies not in isolation but as one of the most reliably anchored landmarks in the educational attainment genetic architecture.

A single nucleotide variant sitting in an intron of the PHACTR1 gene on chromosome 6 has one of the most remarkable genetic profiles in cardiovascular and neurological medicine: its two alleles pull risk in opposite directions across five vascular diseases. Carry the A allele and you are predisposed to migraine headaches, cervical artery dissection, and fibromuscular dysplasia. Carry the G allele and your migraine risk falls — but your risk of coronary artery disease and myocardial infarction rises. The same switch, flipped in opposite directions for two different arteries, illustrates why the PHACTR1 locus has attracted intense interest from both neurologists and cardiologists.

PHACTR1¹¹ PHACTR1
phosphatase and actin regulator 1 — a protein involved in cytoskeletal regulation, vascular compliance, and endothelial gene expression is expressed predominantly in endothelial and vascular smooth muscle cells. The rs9349379 variant lies in a large intron (between exons 5 and 6) but is not silent — it sits in a regulatory enhancer active in aortic tissue and alters the binding of myocyte enhancer factor-2 (MEF2) transcription factors to that enhancer.

The Mechanism

The molecular story has two layers. First, rs9349379 affects PHACTR1's own expression: the G allele disrupts MEF2 binding, reducing PHACTR1 transcription in human coronary arteries and aorta. Wang & Musunuru 2018²² Wang & Musunuru 2018
Circulation Genomic Precision Med confirmed this using CRISPR-edited iPSC-derived endothelial cells with knock-in of each allele — GG homozygotes expressed less PHACTR1 than AA homozygotes.

Second, and more dramatically, rs9349379 acts as a distal enhancer for endothelin-1 (EDN1), located 600 kb upstream of PHACTR1. Gupta et al. 2017³³ Gupta et al. 2017
Cell used CRISPR deletion of the 88-bp regulatory element at rs9349379 in iPSC-derived endothelial cells and vascular smooth muscle cells; deletion increased EDN1 expression, and analysis of 99 healthy individuals confirmed that each G allele raises Big ET-1 plasma levels. Endothelin-1 is a potent vasoconstrictor that also promotes vascular smooth muscle proliferation, extracellular matrix deposition, and arterial fibrosis — effects consistent with coronary plaque vulnerability.

The opposing disease profiles arise because atherosclerotic coronary artery disease (plaque-dependent) and migraine with aura (vasospasm and cortical spreading depression) represent fundamentally different vascular failure modes. Higher ET-1 from the G allele promotes the chronic endothelial injury model of atherosclerosis while the A allele's arterial-wall compliance changes (fibromuscular dysplasia, CeAD) reflect a structural fragility model distinct from plaque. PHACTR1 itself, when reduced by the G allele, may also modulate endothelial inflammation via NF-κB-dependent ICAM-1/VCAM-1 expression.

The Evidence

Hautakangas et al. 2022⁴⁴ Hautakangas et al. 2022
Nature Genetics — the largest migraine GWAS to date (102,084 cases, 771,257 controls) — identified rs9349379 as the sole credible causal variant at the PHACTR1 locus with a posterior inclusion probability of 1.00. The association reached P ≈ 1×10⁻⁴⁷, placing it among the top migraine loci genome-wide. PHACTR1 was one of only two genes prioritized with strong evidence by both gene prioritization methods used in the study. The association held for migraine both with and without aura.

The pleiotropy was formally quantified by Winsvold et al. 2017⁵⁵ Winsvold et al. 2017
PLOS ONE using conjunctional FDR analysis across 23,285 migraine cases and multiple CAD cohorts: the A allele showed beta = +0.073 for migraine (P = 6.4×10⁻⁸) but beta = −0.159 for CAD (P = 6.5×10⁻²¹) — opposite signs, both highly significant.

For cervical artery dissection, Debette et al. 2015⁶⁶ Debette et al. 2015
Nature Genetics found the G allele protective (OR = 0.75, P = 4.5×10⁻¹⁰, 2,052 cases/17,064 controls). For fibromuscular dysplasia, Kiando et al. 2016⁷⁷ Kiando et al. 2016
PLoS Genetics found the A allele confers OR = 1.39 (P = 7.4×10⁻¹⁰, 1,154 FMD cases). The A allele is rare in Africans (~8%) but common in East Asians (~32% homozygous AA), producing dramatically different population-level vascular disease burdens.

Practical Actions

For carriers of the AA genotype (two A alleles): migraine susceptibility is elevated, and while the vascular mechanism is distinct from classical atherosclerosis, the endothelial and arterial-wall changes associated with the A allele also raise risk of cervical artery dissection and fibromuscular dysplasia. Vasoconstrictive migraine treatments (ergotamine, dihydroergotamine) carry theoretical concern in individuals already predisposed to arterial wall pathology, and triptans — which carry black-box warnings for coronary vasospasm — are worth discussing with a neurologist who knows this genotype.

For GG carriers: migraine risk is low, but the G allele's higher ET-1 production and reduced PHACTR1 expression increase coronary artery disease risk independently of traditional risk factors. Standard cardiovascular risk management is therefore especially important.

Interactions

The PHACTR1 locus interacts at the pathway level with other vascular endothelial variants. The EDN1 pathway is shared with rs5370 (EDN1 Lys198Asn), which directly alters the endothelin-1 peptide sequence and affects vasoconstrictor tone. Variants in EDNRA and EDNRB (endothelin receptor genes) could compound the rs9349379 regulatory effect on ET-1 signalling. NOS3 variants (e.g., rs1799983 ENOS Glu298Asp) affecting nitric oxide production operate antagonistically to endothelin-1 in vascular tone regulation; a combined PHACTR1-AA / NOS3-risk genotype may produce additive vascular wall dysfunction. These pathway interactions are candidates for compound actions but require published evidence of combined effects before they can be formally modelled.